ReviewCurrent oncology reports2013
Melanoma brain metastases: an unmet challenge in the era of active therapy.
Review in Current oncology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Investigating the functions and molecular mechanisms of DTX3L in cancer progression.Frontiers in oncology · 2026Review
- Treatment patterns and outcomes in melanoma brain metastasis: exploring immune-related adverse events and survival.Immunotherapy · 2025Article
- Article
- Outcomes of Treatment for Melanoma Brain Metastases.Journal of skin cancer · 2020Article
- Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.Frontiers in immunology · 2020Article
- Molecular and cellular stratagem of brain metastases associated with melanoma.Oncology letters · 2019Review
- Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.Pharmaceutical research · 2018Review
- Validation of the Chowdhury overall survival score in patients with melanoma brain metastasis treated with Gamma Knife Radiosurgery.Journal of neuro-oncology · 2018Article
- Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018Review
- Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.Clinical proteomics · 2018Article
- Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma.Cureus · 2017Article
- Review
- Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?Pharmacological research · 2017Article
- Brain metastases from hepatocellular carcinoma: recent advances and future avenues.Oncotarget · 2017Review
- Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Neuro-oncology · 2017Review
- Challenges in the delivery of therapies to melanoma brain metastases.Current pharmacology reports · 2016Article
- Melanoma Brain Metastasis: Mechanisms, Models, and Medicine.International journal of molecular sciences · 2016Review
- Metastatic melanoma of the gallbladder: report of two cases and a review of the literature.Clinical and experimental medicine · 2016Review
- Embracing rejection: Immunologic trends in brain metastasis.Oncoimmunology · 2016Review
- Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases.Radiation oncology (London, England) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Metastatic disease to the brain is a frequent manifestation of melanoma and is associated with significant morbidity and mortality and poor prognosis. Surgery and stereotactic radiosurgery provide local control but less frequently affect the overall outcome of melanoma brain metastases (MBM). The role of systemic therapies for active brain lesions has been largely underinvestigated, and patients with active brain lesions are excluded from the vast majority of clinical trials. The advent of active systemic therapy has revolutionized the care of melanoma patients, but this benefit has not been systematically translated into intracranial activity. In this article, we review the biology and clinical outcomes of patients with MBM, and the evidence supporting the use of radiation, surgery, and systemic therapy in MBM. Prospective studies that included patients with active MBM have shown clinical intracranial activity that parallels systemic activity and support the inclusion of patients with active MBM in clinical trials involving novel agents and combination therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.